Risk factors associated with irreversible airflow limitation in asthma

Current Opinion in Allergy and Clinical Immunology

Volumn 8, Issue 1, 2008, Pages 63-69

  Ten Brinke, Anneke ^a  

^a MEDICAL CENTER LEEUWARDEN   (Netherlands)

Author keywords

Airway remodeling; Asthma; Persistent airflow limitation; Risk factor

Indexed keywords

ASTHMA; BRONCHUS HYPERREACTIVITY; BRONCHUS MUSCLE; GENETIC POLYMORPHISM; HUMAN; OCCUPATIONAL EXPOSURE; ONSET AGE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY AIRFLOW; RESPIRATORY EPITHELIUM; REVIEW; RISK FACTOR; SMOKING;

ADAM PROTEINS; ADULT; AGE FACTORS; AIRWAY OBSTRUCTION; ASTHMA; BACTERIAL INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; DISEASE PROGRESSION; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MYCOPLASMA PULMONIS; RESPIRATORY MUCOSA; RESPIRATORY SYSTEM; RISK FACTORS; SEX FACTORS; SMOKING; TOBACCO SMOKE POLLUTION;

EID: 38049105621     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e3282f3b5b5     Document Type: Review

References (35)

1. Bel EH. Clinical phenotypes of asthma. Curr Opin Pulm Med 2004; 10:44-50.
2. Lange P, Parner J, Vestbo J, et al. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 1998; 339:1194-1200.
3. Ulrik CS, Lange P. Decline of lung function in adults with bronchial asthma. Am J Respir Crit Care Med 1994; 150:629-634.
4. Vonk JM, Jongepier H, Panhuysen CI, et al. Risk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 26 years of follow up. Thorax 2003; 58:322-327.
5. ten Brinke A, Zwinderman AH, Sterk PJ, et al. Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med 2001; 164:744-748.
6. Panizza JA, James AL, Ryan G, et al. Mortality and airflow obstruction in asthma: a 17-year follow-up study. Intern Med J 2006; 36:773-780.
7. Hansen EF, Phanareth K, Laursen LC, et al. Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159:1267-1271.
8. Bumbacea D, Campbell D, Nguyen L, et al. Parameters associated with persistent airflow obstruction in chronic severe asthma. Eur Respir J 2004; 24:122-128.
9. Phelan PD, Robertson CF, Olinsky A. The Melbourne Asthma Study: 1964-1999. J Allergy Clin Immunol 2002; 109:189-194.
10. de Marco R, Marcon A, Jarvis D, et al. Inhaled steroids are associated with reduced lung function decline in subjects with asthma with elevated total IgE. J Allergy Clin Immunol 2007; 119:611-617.
11. James AL, Palmer LJ, Kicic E, et al. Decline in lung function in the Busselton Health Study: the effects of asthma and cigarette smoking. Am J Respir Crit Care Med 2005; 171:109-114.
12. Rasmussen F, Taylor DR, Flannery EM, et al. Risk factors for airway remodeling in asthma manifested by a low postbronchodilator FEV1/vital capacity ratio: a longitudinal population study from childhood to adulthood. Am J Respir Crit Care Med 2002; 165:1480-1488.
13. Bai TR, Vonk JM, Postma DS, Boezen HM. Severe exacerbations predict excess lung function decline in asthma. Eur Respir J 2007; 30:452-456.
14. Wood LG, Powell H, Grissell T, et al. Persistent airway obstruction after virus infection is not associated with airway inflammation. Chest 2007; 131:415-423.
15. Convery RP, Leitch DN, Bromly C, et al. Effect of inhaled fluticasone propionate on airway responsiveness in treatment-naive individuals-a lesser benefit in females. Eur Respir J 2000; 15:19-24.
16. Dijkstra A, Vonk JM, Jongepier H, et al. Lung function decline in asthma: association with inhaled corticosteroids, smoking and sex. Thorax 2006; 61:105-110.
17. Dijkstra A, Howard TD, Vonk JM, et al. Estrogen receptor 1 polymorphisms are associated with airway hyperresponsiveness and lung function decline, particularly in female subjects with asthma. J Allergy Clin Immunol 2006; 117:604-611.
18. Miranda C, Busacker A, Balzar S, et al. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol 2004; 113:101-108.
19. Moore WC, Bleecker ER, Curran-Everett D, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 2007; 119:405-413. This study describes the comprehensive phenotypic characterization performed in a large cohort of patients with severe asthma in comparison with asthma that is not severe.
20. ten Brinke A, van Dissel JT, Sterk PJ, et al. Persistent airflow limitation in adult-onset nonatopic asthma is associated with serologic evidence of Chlamydia pneumoniae infection. J Allergy Clin Immunol 2001; 107:449-454.
21. Goksor E, Amark M, Alm B, et al. The impact of pre and postnatal smoke exposure on future asthma and bronchial hyper-responsiveness. Acta Paediatr 2007; 96:1030-1035.
22. Van Eerdewegh P, Little RD, Dupuis J, et al. Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature 2002; 418:426-430.
23. Jongepier H, Boezen HM, Dijkstra A, et al. Polymorphisms of the ADAM33 gene are associated with accelerated lung function decline in asthma. Clin Exp Allergy 2004; 34:757-760.
24. Lee JY, Park SW, Chang HK, et al. A disintegrin and metalloproteinase 33 protein in patients with asthma: relevance to airflow limitation. Am J Respir Crit Care Med 2006; 173:729-735. This study shows the relationship between levels of ADAM33 protein in bronchoalveolar lavage fluids and severity of airway obstruction.
25. Foley SC, Mogas AK, Olivenstein R, et al. Increased expression of ADAM33 and ADAM8 with disease progression in asthma. J Allergy Clin Immunol 2007; 119:863-871.
26. Holgate ST, Yang Y, Haitchi HM, et al. The genetics of asthma: ADAM33 as an example of a susceptibility gene. Proc Am Thorac Soc 2006; 3:440-443. This recent review focuses on the role of ADAM33 in asthma.
27. van Diemen CC, Postma DS, Vonk JM, et al. A disintegrin and metalloprotease 33 polymorphisms and lung function decline in the general population. Am J Respir Crit Care Med 2005; 172:329-333.
28. Simpson A, Maniatis N, Jury F, et al. Polymorphisms in a disintegrin and metalloprotease 33 (ADAM33) predict impaired early-life lung function. Am J Respir Crit Care Med 2005; 172:55-60.
29. Boulet LP, Lemiere C, Archambault F, et al. Smoking and asthma: clinical and radiologic features, lung function, and airway inflammation. Chest 2006; 129:661-668.
30. Barnes PJ, Ito K, Adcock IM. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet 2004; 363:731-733.
31. Anees W, Moore VC, Burge PS. FEV1 decline in occupational asthma. Thorax 2006; 61:751-755.
32. Park HW, Kim DI, Sohn SW, et al. Outcomes in occupational asthma caused by reactive dye after long-term avoidance. Clin Exp Allergy 2007; 37:225-230.
33. Pasternack R, Huhtala H, Karjalainen J. Chlamydophila (Chlamydia) pneumoniae serology and asthma in adults: a longitudinal analysis. J Allergy Clin Immunol 2005; 116:1123-1128.
34. Ulrik CS, Backer V. Nonreversible airflow obstruction in life-long nonsmokers with moderate to severe asthma. Eur Respir J 1999; 14:892-896.
35. Brutsche MH, Downs SH, Schindler C, et al. Bronchial hyperresponsiveness and the development of asthma and COPD in asymptomatic individuals: SAPALDIA cohort study. Thorax 2006; 61:671-677.